Veirulence Ltd, a pioneering biotechnology company dedicated to combating antimicrobial resistance (AMR), has successfully raised $2,000,000 in a recent funding round. This critical investment underscores the urgency of addressing the escalating global health crisis posed by resistant bacteria, particularly in light of the World Health Organization's identification of Pseudomonas aeruginosa as a priority pathogen due to its association with severe hospital-acquired infections. Veirulence's innovative approach focuses on the virulence factors that enable bacteria to thrive and spread disease. Their groundbreaking small molecule specifically targets swarming—a pivotal virulence factor of P. aeruginosa—effectively preventing the pathogen from establishing infections while also enhancing the efficacy of existing antibiotics when used in tandem. The funds raised will be directed towards crucial research and development efforts to bring this novel treatment closer to clinical application, addressing the significant unmet medical needs in bacterial infection management. With rising rates of antibiotic resistance, Veirulence is poised to make a substantial impact on public health by not only halting infections but also improving patient outcomes in acute infection scenarios. The support from investors highlights a growing recognition of the urgent need for innovative solutions in the fight against AMR, and Veirulence Ltd is committed to leading the charge in developing cutting-edge therapies that safeguard global health.

Veirulence Ltd Secures $2 Million in Seed Funding for Groundbreaking Anti-Resistance Bacterial Treatment Innovation
Get the full Veirulence Ltd company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Centricity WealthTech
Founded in January 2022, Centricity helps empower finance and investment professionals aspiring to establish their independent practices. The platform aims to deliver a comprehensive SAAS based investment management platform including digital transactional capabilities for a diversified product suite. Wealth management professionals prefer focusing on their clients’ interests and not their employers ever-changing priorities. Also, clients want stability and not a relentless institutional product push. We are looking to bring in consistency of the family office experience for a spectrum of investors across emerging affluent, affluent and high net worth categories. We are boutique by design and an institution by default.
$30.0M Series a
today

MigmaAI
Create, design and send on-brand emails in seconds.
$330.0K Pre-seed
today

Multiverse
Multiverse is the upskilling platform for AI and tech adoption. We’ve built a new model for transforming today’s workforce by combining expert human coaching with AI. Our learning drives real business impact and helps organisations close critical skills gaps - especially in data, AI and all things tech. We’ve already partnered with over 1,500 global organisations to transform their workforce through tech skills. Trusted by Microsoft, Mars, John Lewis Partnership and many more to upskill their team and unlock people’s potential and output. In 2022, we raised our $220m Series D funding - one of the largest venture rounds in EdTech history. We’re proud to be backed by some of the world’s biggest investors, including General Catalyst, Lightspeed Venture Partners and StepStone Group.
$70.0M Unknown
today

SWELL Sculpture Festival
SWELL Sculpture Festival (SWELL) is a multifaceted arts organisation that connects people, art, and place, based in Currumbin, Gold Coast, Queensland. Since 2003 SWELL has exhibited 873 Sculptures in the main exhibition on Currumbin Beach with a portfolio value worth $15.5M.
$5.5K Grant
today

Parcel Health
Healthcare and pharmacies' supply chain runs on expensive plastic. Billions of units of disposable, single-use supplies and packaging — most of it never questioned, never redesigned, never replaced. Paid for at a premium to budgets and to the environment. Until now. Parcel Health is reimagining healthcare supplies, creating products that can protect people and preserve the planet, all at an affordable price point. Tully Tube® is the world's first and only paper pill bottle that meets U.S. regulatory requirements. It is trusted by leading hospital health-systems like Dartmouth-Hitchcock Health System, Allegheny Health Network, and Wellstar Health System. This is just the beginning. Parcel Health is building a future where healthcare supplies are safer for patients, better for the planet, and easier on budgets.
$1.2M Seed
today
Other recent Seed rounds
Companies that recently closed a Seed round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | ![]() Parcel Health United States | Seed | $1.2M | today |
| 2 | ![]() Envoke Canada | Seed | $1.6M | today |
| 3 | ![]() H2CHP Limited United Kingdom | Seed | $1.5M | today |
| 4 | ![]() Synthetic Brazil | Seed | $10.0M | 1d ago |
| 5 | ![]() harva. (formerly Supply Pay) United States | Seed | $113.0M | 1d ago |



.png&w=3840&q=75)